Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents
The concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs did not contribute to clinically meaningful changes in the risk of thrombosis or bleeding in individuals with prostate cancer.
Authors
- Manish M. Sood (ORCID: https://orcid.org/0000-0002-9146-2344)
- Mitchell Rath
- Pietro Ravani (ORCID: https://orcid.org/0000-0001-6973-8570)
- Deena Fremont (ORCID: https://orcid.org/0009-0006-8670-2813)
- Anna Clarke
- Samantha Yoo
- Tzu‐Fei Wang
- Dominick Bosse
- Robert Talarico
- Marc Carrier
- Cynthia Wu
Institutions
- Alberta Health Services (CA)
- University of Alberta (CA)
- University of Calgary (CA)
- Ottawa Hospital (CA)
- Ottawa Hospital Research Institute (CA)
Publication Details
- Journal
- Cancer
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1002/cncr.70266
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Alberta Health Services
- University of Ottawa
- Cancer Care Ontario
- University of Alberta
- Ontario Ministry of Health and Long-Term Care
- Alberta Innovates
- Canadian Institutes of Health Research